:: Hypoparathyroidism UK ::

First UK clinical study on PTH 1-84

There is currently no approved replacement therapy for hypoparathyroidism.

But we're working on it! HPTH UK are involved in the first UK clinical trial on the use of parathyroid hormone (PTH 1-84) for the treatment of Hypoparathyroidism, which is currently recruiting in Liverpool as part of a global study sponsored by NPS Pharmaceuticals Inc. (The Oxford study centre is now closed as not enough patients could be recruited in the area.)

We still need patients to take part

The news from patients currently on the trial is very positive. Would you like to join these pioneers? Be one of the lucky ones to try PTH for youself and help future HPTH patients to have a better life.

Interested?

To take part you must be a UK member aged 18 - 65, have had HPTH for at least 18 months and be on Vitamin D and calcium treatment. Check other criteria here to make sure you are eligible.

Changes to these criteria have recently been made. If you live more than 40 miles outside Liverpool , NPS are willing to pay reasonable travel and accomodation costs. You may also now apply if you are of child bearing age, on contraception and willing to have a pregnancy test.

How do I apply?

Simple. If you have checked all the criteria please download this form complete it and return it to us as soon as possible. We will forward it to the appropriate research team who will then contact you.

You will be able to discuss the study in detail with the doctor before choosing whether to participate and you may withdraw at any point. There will be a screening period to check you are suitable. If you have any questions about your eligibility, please contact us.

Thank you

NPS Pharmaceuticals, a company which specialises in developing therapies for rare endocrine disorders, is currently running a Phase 3 registration study, known as REPLACE, to evaluate NPSP558 for the treatment of adults with hypoparathyroidism. NPSP558 is a proprietary recombinant full-length human parathyroid hormone (PTH 1-84), which mimics the action of natural parathyroid hormone.

The primary objective is to demonstrate, over a 24-week treatment period, that once-daily subcutaneous dosing with NPSP558 at doses of 50mcg, 75mcg or 100mcg is a safe and effective hormone replacement therapy for the treatment of patients with hypoparathyroidism. For more information on REPLACE, please contact NPS Pharmaceuticals, Inc. http://www.npsp.com

We hope that positive results from this trial will

- enable NPS to seek US and UK marketing approval for PTH 1-84 for the treatment of Hypoparathyroidism.

- lead to a safer and more reliable means of treatment for HPTH patients all over the world

- lead to a significant decrease in the severe renal outcomes that are currently being experienced by patients on vitamin d and calcium therapy. (How it will affect bone turnover remains to be seen.)

- help to further knowledge and understanding of Hypoparathyroidism.

------------------------------------------------------------------------------------------------

For further information about taking part in a clinical trial dna for details of other trials which are currently recruiting please click here

-----------------------------------------------------------------------------------------------

Join in the discussion with patients already on parathyroid hormone on our forum or facebook page.

-------------------------------------------------------------------------------------------------